Dr. Moskowitz on the Challenges of Intensifying Treatment in Hodgkin Lymphoma

Video

Alison J. Moskowitz, MD, discusses the challenges of intensifying treatment in Hodgkin lymphoma.

Alison J. Moskowitz, MD, medical oncologist, clinical director, Lymphoma, Memorial Sloan Kettering Cancer Center, discusses the challenges of intensifying treatment in Hodgkin lymphoma. 

In Hodgkin lymphoma, research efforts are ongoing to determine whether intensifying frontline treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is feasible for patients, Moskowitz says. 

The most important goal of front-line therapy is to balance efficacy with toxicity, Moskowitz explains. Moreover, it is inefficient to utilize highly aggressive regimens if the patient could encounter substantial toxicities, Moskowitz adds.

This is especially important to consider in Hodgkin Lymphoma because the primary patient population comprises younger individuals. As such, these patients likely have many decades to live, so reducing long-term toxicity is a key consideration in treatment selection, Moskowitz concludes.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD